Cargando…

Histone Deacetylase Inhibitors and Mithramycin A Impact a Similar Neuroprotective Pathway at a Crossroad between Cancer and Neurodegeneration

Mithramycin A (MTM) and histone deacetylase inhibitors (HDACi) are effective therapeutic agents for cancer and neurodegenerative diseases. MTM is a FDA approved aureolic acid-type antibiotic that binds to GC-rich DNA sequences and interferes with Sp1 transcription factor binding to its target sites...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sleiman, Sama F., Berlin, Jill, Basso, Manuela, S.Karuppagounder, Saravanan, Rohr, Jürgen, Ratan, Rajiv R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2011
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3349345/ https://www.ncbi.nlm.nih.gov/pubmed/22582024 http://dx.doi.org/10.3390/ph4081183

Ejemplares similares

Ferroptosis in Neurons and Cancer Cells Is Similar But Differentially Regulated by Histone Deacetylase Inhibitors
por: Zille, Marietta, et al.
Publicado: (2019)

Mithramycin interacts with core histones and modulates epigenetic modifications
por: Banerjee, Amrita, et al.
Publicado: (2013)

Mithramycin and Analogs for Overcoming Cisplatin Resistance in Ovarian Cancer
por: Schweer, David, et al.
Publicado: (2021)

Nanoparticulate formulations of mithramycin analogs for enhanced cytotoxicity
por: Scott, Daniel, et al.
Publicado: (2011)

Histone Deacetylases Inhibitors in Neurodegenerative Diseases, Neuroprotection and Neuronal Differentiation
por: Shukla, Surabhi, et al.
Publicado: (2020)

Anticancer drug mithramycin interacts with core histones: An additional mode of action of the DNA groove binder
por: Banerjee, Amrita, et al.
Publicado: (2014)

Histone deacetylase inhibition leads to neuroprotection through regulation on glial function
por: Wu, Xuefei, et al.
Publicado: (2013)

Exercise promotes the expression of brain derived neurotrophic factor (BDNF) through the action of the ketone body β-hydroxybutyrate
por: Sleiman, Sama F, et al.
Publicado: (2016)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

UBA1: At the Crossroads of Ubiquitin Homeostasis and Neurodegeneration
por: Groen, Ewout J.N., et al.
Publicado: (2015)

TAM Receptor Pathways at the Crossroads of Neuroinflammation and Neurodegeneration
por: Tondo, Giacomo, et al.
Publicado: (2019)

The histone deacetylase inhibitor nicotinamide exacerbates neurodegeneration in the lactacystin rat model of Parkinson's disease
por: Harrison, Ian F., et al.
Publicado: (2018)

Structures of mithramycin analogues bound to DNA and implications for targeting transcription factor FLI1
por: Hou, Caixia, et al.
Publicado: (2016)

Histones: At the Crossroads of Peptide and Protein Chemistry
por: Müller, Manuel M., et al.
Publicado: (2014)

Autophagy impairment: a crossroad between neurodegeneration and tauopathies
por: Nassif, Melissa, et al.
Publicado: (2012)

Cytokines and Chemokines at the Crossroads of Neuroinflammation, Neurodegeneration, and Neuropathic Pain
por: Ramesh, Geeta, et al.
Publicado: (2013)

The SMN Complex at the Crossroad between RNA Metabolism and Neurodegeneration
por: Faravelli, Irene, et al.
Publicado: (2023)

A STING agonist preconditions against ischaemic stroke via an adaptive antiviral Type 1 interferon response
por: Kundu, Nandini, et al.
Publicado: (2022)

A trial of mithramycin in the treatment of advanced malignant disease.
por: Sewell, I. A., et al.
Publicado: (1966)

Mithramycin delivery systems to develop effective therapies in sarcomas
por: Estupiñán, Óscar, et al.
Publicado: (2021)

Mithramycin induces promoter reprogramming and differentiation of rhabdoid tumor
por: Chasse, Maggie H, et al.
Publicado: (2020)

Beyond Histone and Deacetylase: An Overview of Cytoplasmic Histone Deacetylases and Their Nonhistone Substrates
por: Yao, Ya-Li, et al.
Publicado: (2011)

Oxidative Stress, a Crossroad between Rare Diseases and Neurodegeneration
por: Espinós, Carmen, et al.
Publicado: (2020)

Histone Deacetylase Inhibitors: A Novel Strategy for Neuroprotection and Cardioprotection Following Ischemia/Reperfusion Injury
por: Pickell, Zachary, et al.
Publicado: (2020)

Neurodegeneration and Neuroprotection in Glaucoma
por: Gauthier, Angela C., et al.
Publicado: (2016)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

The drug adaptaquin blocks ATF4/CHOP-dependent pro-death Trib3 induction and protects in cellular and mouse models of Parkinson’s disease
por: Aimé, Pascaline, et al.
Publicado: (2020)

A clinical trial of mithramycin in the treatment of advanced malignant disease.
por: Baum, M.
Publicado: (1968)

Nano-Encapsulation of Mithramycin in Transfersomes and Polymeric Micelles for the Treatment of Sarcomas
por: Estupiñán, Óscar, et al.
Publicado: (2021)

DMT1 Expression and Iron Levels at the Crossroads Between Aging and Neurodegeneration
por: Ingrassia, Rosaria, et al.
Publicado: (2019)

The potential neuroprotective role of a histone deacetylase inhibitor, sodium butyrate, after neonatal hypoxia-ischemia
por: Jaworska, Joanna, et al.
Publicado: (2017)

Chemical Phylogenetics of Histone Deacetylases
por: Bradner, James E., et al.
Publicado: (2010)

Histone deacetylases in viral infections
por: Herbein, Georges, et al.
Publicado: (2010)

Butyrate Histone Deacetylase Inhibitors
por: Steliou, Kosta, et al.
Publicado: (2012)

Histone deacetylase signaling in cardioprotection
por: Lehmann, Lorenz H., et al.
Publicado: (2013)

Histone deacetylase 6 in cancer
por: Li, Ting, et al.
Publicado: (2018)

Neurodegeneration and neuroprotection in Parkinson's disease /
Publicado: (1996)

Neurodegeneration and Neuroprotection in Diabetic Retinopathy
por: Ola, Mohammad Shamsul, et al.
Publicado: (2013)

Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8
por: Yan, Wensheng, et al.
Publicado: (2012)

Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors
por: Lapierre, Marion, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_dgd75hg5v7aq02b450rib3oj2g